Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acetaminophen Risk Management On Tap For Joint Advisory Panel

This article was originally published in The Tan Sheet

Executive Summary

FDA is looking for risk-management solutions to liver problems linked to the misuse of acetaminophen in OTC and prescription products, and will convene a joint advisory panel to discuss potential steps to take

You may also be interested in...



Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data

A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks

Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data

A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks

Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data

A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS102838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel